Starpharma 

Starpharma Holdings Limited is a global biopharmaceutical firm dedicated to the investigation, advancement, and marketing of its proprietary dendrimer-based products for pharmaceutical, life science, and other diverse applications. Among its commercialized offerings is VivaGel, an antibiotic-free therapy designed for both preventing and managing bacterial vaginosis. The company's pipeline also features the VivaGel antiviral condom and VIRALEZE, an antiviral nasal spray. A cornerstone of Starpharma's innovation is its Dendrimer Enhanced Product (DEP) drug delivery platform. This advanced technology is being leveraged to develop a diverse portfolio of treatments, particularly in oncology. Several DEP-enhanced cancer therapies are currently progressing through clinical trials: DEP docetaxel, DEP cabazitaxel, and DEP irinotecan are all in Phase 2 studies, while DEP gemcitabine is undergoing Phase 1/2 trials. The DEP platform's utility extends further to radiotheranostics for cancer diagnosis and treatment, various Antibody Drug Conjugates (including DEP HER-2 ADC), and other non-oncology candidates. Additionally, DEP AZD0466 is advancing through Phase 1/2 clinical trials specifically for haematological malignancies. Starpharma Holdings Limited was established in 1996 and is headquartered in Abbotsford, Australia.